Showing results (61-70 of 73) with videos related to
Sort By:
Pageof 8
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 16, 2023
Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal studyYusuke Hiratsuka, Keita Tagami, Akira Inoue, et al.Journal of Pain and Symptom Management|June 30, 2019
Additive Duloxetine for Cancer-Related Neuropathic Pain Nonresponsive or Intolerant to Opioid-Pregabalin Therapy: A Randomized Controlled Trial (JORTC-PAL08)Hiromichi Matsuoka, Satoru Iwase, Tempei Miyaji, et al.BMJ Open|July 17, 2026
Multicentre, double-blind, randomised, placebo-controlled study on the prophylactic use of naldemedine for opioid-induced nausea and vomiting in patients with cancer (POSEIDON study): a protocol paperYo Ishihara, Mayumi Ohira, Mitsuki Hokabe, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 26, 2019
Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial-JORTC-PAL08 (DIRECT) studyHiromichi Matsuoka, Satoru Iwase, Tempei Miyaji, et al.International Journal of Clinical Oncology|May 16, 2024
2023 Japan Society of clinical oncology clinical practice guidelines update for antiemesisHirotoshi Iihara, Masakazu Abe, Makoto Wada, et al.Pharmacological Research|January 30, 2026
Pain signaling via sensory neurons drives breast cancer progression through neuropeptide release and κ-opioid counter-regulationHitoshi Makabe, Michiko Narita, Yasuyuki Nagumo, et al.International Journal of Clinical Oncology|July 21, 2026
Systematic review of antiemetic therapy for low emetogenic chemotherapy: comparing 5-HT3 receptor antagonists and dexamethasoneTakeshi Aoyama, Hirotoshi Iihara, Masakazu Abe, et al.International Journal of Clinical Oncology|November 12, 2024
Efficacy and safety of multi-day antiemetic treatment for patients undergoing multi-day chemotherapy: a systematic review of Clinical Practice Guidelines for Antiemesis 2023 from Japan Society of Clinical OncologyKazuhisa Nakashima, Saki Harashima, Rena Kaneko, et al.International Journal of Clinical Oncology|November 21, 2024
Clinical benefits of adding olanzapine to 5-HT3 receptor antagonist, NK1 receptor antagonist, and dexamethasone for the prevention of nausea and vomiting in highly emetogenic chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical OncologyMichiyasu Murakami, Yoshiharu Miyata, Kazuhisa Nakashima, et al.International Journal of Clinical Oncology|May 9, 2024
Non-pharmacological treatments for anticipatory nausea and vomiting during chemotherapy: a systematic review and meta-analysis of the Clinical Practice Guidelines for Antiemesis 2023Masamitsu Kobayashi, Jun Kako, Arisa Iba, et al.Pageof 8